41 results about "Anti mrsa" patented technology

The invention relates to azaphilones compounds in marine fungus HK1-6 and an application of the azaphilones compounds as an MRSA-resistant drug, in particular to secondary metabolites 1-4 produced bymarine fungus Penicillium sp.HK1-6 or pharmaceutically acceptable salt. The compounds 1-4 show very high antibacterial activity for MRSA (such as S. aureus ATCC4330 and S. aureus ATCC33591) and VER (such as E. faecalis ATCC51299), MIC is smaller than or equal to 12.5 mu g / mL, the MIC of a compound 2 for E. faecalis ATCC51299 is one times higher than that of positive drug vancomycin, and the compounds have good prospects to be developed into drugs resisting drug-resistant bacteria, lead compounds of drugs and candidate drugs.

The invention relates to application of the combination of any two or three combined catechin substances with antibiotics in preparing antibacterial drugs. The combination of the combined catechin substances with the antibiotics is applied to the field of resisting MRSA (Methicillin-Resistant Staphylococcus Sureus) and can provide the antibacterial and sensitivity increasing effects of drugs. The invention not only broadens the application of the catechin substances and the application scheme thereof, but also can reduce the phenomena of drug resistance generated by the MRSA due to the abuse of the traditional antibacterial drugs.

The invention relates to antisense oligonucleotides aiming to methicillin-resistant Staphylococcus aureus (MRSA) resistance gene mecR1 / mecA and blaR1 / blaZ and a preparation of the drugs with the antisense oligonucleotides and the application thereof. The antisense oligonucleotides comprise antisense phosphorothiate oligodeoxynucleotide (PS-ODNs) and thiodeoxyribozyme (PS-DRz). The invention is characterized in that the combination of the specificity and the various areas of MRSA resistance gene mecR1 / mecA and blaR1 / blaZ blocks the expression of the resistance gene, the base sequence of the antisense nucleic acid is PS-ODNs01-40, the antisense nucleic acid can combine with the specific site of the target gene, thereby inhibiting the expression of the resistance gene, causing MRSA to restore the sensitivity of the lactam antibiotics and achieving the purpose of effective fighting with the drug resistance of MRSA.

The present invention aims at preventing foodborne infections. As a candidate for this purpose, the inventors focused on antibacterial acidic liquid diets, which are acidic due to comprising fermented dairy products as protein source. The antibacterial activity of the acidic liquid diets was compared with the antibacterial activity of a neutral liquid diet and the fermented dairy product used as the basic ingredient. Antibacterial effect of fermented milk such as yogurt is already known. However, the acidic liquid diets unexpectedly exhibited an antibacterial effect higher than the basic ingredient (the fermented dairy product) against Gram-positive bacteria such as MRSA, which are important in terms of public health.

An anti-“Methicillin-Resistant Staphylococcus Aureus (MRSA)” chitosan containing antibacterial High Wet Modulus (HWM) rayon fiber textile for medical usage is made of the steps as following: chitin flakes made from natural shrimp or crab shells are deacetylated to generate chitosan with a high deacetylation degree of 90% or more. Next chitosan is dissolved in acetic acid and regenerated by caustic soda to form a chitosan antibacterial nanoparticles slurry, then added to HWM viscose rayon process, and spinning to produce a chitosan containing antibacterial HWM rayon fiber. The antibacterial amino groups of chitosan and the hydroxyl groups of rayon cellulose combine together via hydrogen bonding. Therefore, the fiber becomes the anti-MRSA antibacterial HWM rayon fiber containing amino groups (—NH3+). Finally the resulting HWM rayon fiber is conducted via a yarn spinning or / and weaving process to procure a medical textile with chitosan content.

One kind of union biosensor technology and isolation technique, From natural medicine, selection and separation have the combination PBP2a active method of organizing minute or active material, the method will PBP2a coating on the sample pool biosensor match as a solid base to extract natural medicines the mobile phase of the selected combination with PBP2a in the role of natural medicine, will be an integrated component of the higher value after isolation and purification, has been a collaborative antagonistic MRSA activity combined with PBP2a occurred role of the active component, the Preparation synergistic components can be used to beta - lactam antibiotics treatment of MRSA infection drugs or lead compounds. This method has time-saving, the high flux, to reduce effort, the specificity to be strong, the result accurate, can real-time monitoring many kinds of merits.

Pharmaceutical compositions containing a carbapenem of the structural formula Iand epicillin are strongly bactericidal against MRSA and MRSE. Equivalently, compositions of conventional carbapenem antibiotics and epicillin are highly synergistic in eradicating said bacteria.

The invention specifically relates to gorgonian-originated fungus secondary metabolite derivatives and application of the same as antiseptics, belonging to the field of medicine. The derivatives provided by the invention exert strong inhibitory effect on methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE) and certain inhibitory effect on Gram-negative bacteria; and the minimal inhibition concentrations MIC of the derivatives are all less than 12.5 mu M, which proves that the derivatives can be developed into potential antibacterial drugs.

The invention discloses a recombinant protein of active segment IsdB2 of decision protein IsdB on the surface of methicillin-resistant staphylococcus aureus iron ion, wherein the amino acid sequence of the recombinant protein is SEQ ID No: 3 or the sequence which has the same or similar function as the SEQ ID No: 3 obtained by adding or deleting a plurality of amino acids at the amino terminal and / or the carboxyl terminal of the SEQ ID No: 3. The invention further discloses a method for preparing the recombinant protein by building the expression vector of the recombinant protein and transforming the host bacteria, and the use of the recombinant protein in the aspect of preparing the subunit vaccine and the related assay kits resisting the methicillin-resistant staphylococcus aureus. By adopting the gene engineering technology, in the invention, the truncated protective antigens component IsdB2 is expressed by cloning through the protein expressing, thereby being high in expression index, convenient to separate and purify, and high-efficiency and safe. Due to the gene engineering, the recombinant polyvaccine has good immune protective effect on resisting the MRSA (methicillin-resistant staphylococcus aureus) infection.

The invention discloses a macrolide compound, a synthetic method of the macrolide compound, a pharmaceutical composition and application. The macrolide compound or pharmaceutically acceptable salt thereof shows certain separate anti-MRSA (methicillin-resistant staphylococcus aureus) activity and can further remarkably increase the MRSA inhibiting function of beta-lactam antibiotics when jointly used with the beta-lactam antibiotics. Test results show that the macrolide compound or pharmaceutically acceptable salt has good in-vitro synergism, is a novel synergist, can relieve drug resistance ofthe MRSA to oxacillin and is a drug with good market development prospects.

The invention specifically discloses an antibacterial composition and a wound dressing containing the same. The antibacterial composition comprises a litsea pungens extract and a bletilla striata extract; and the weight ratio of the litsea pungens extract to the bletilla striata extract is 3-5: 2. The litsea pungens extract is prepared by a method comprising the following steps: extracting a traditional Chinese medicine litsea pungens with ethanol to obtain a litsea pungens ethanol extract; and performing silica gel column chromatography on the litsea pungens ethanol extract to obtain the litsea pungens extract. The bletilla striata extract is prepared by a method comprising the following steps: extracting a traditional Chinese medicine bletilla striata with ethanol to obtain bletilla striata ethanol extract; and performing ODS column chromatography on the bletilla striata ethanol extract to obtain the bletilla striata extract. The antibacterial composition has a good antibacterial effect, and especially has an excellent MRSA resistance effect. When the antibacterial composition is applied to the wound dressing, wound bacterial infection can be effectively prevented, and particularly MRSA infection can be prevented.

The invention provides a novel 3D-printing PCL-vancomycin anti-infection bone tissue engineering scaffold, and a preparation method and an application thereof and belongs to bioengineering human implants. In the engineering scaffold, poly-epsilon-caprolactone and vancomycin respectively serve as a base material A and an anti-MRSA medicine B, wherein the A is heated by a heating system in a meltingextrusive shaping 3D printer to form a liquid substance C; then in a FDM extrusion channel, the C is gradually cooled and meanwhile is mixed with a solution, containing the B, at a spinning nozzle ofthe 3D printer, thus extruding shaped fiber bundle D; by means of the jointing structure of different layers and angles of the fiber bundles D, the product is produced through steps of room temperature shaping at 23 DEG C, drying, and ethylene oxide disinfection. The scaffold has simple and reliable structure, controllable appearance and microstructure, reliable mechanical properties and controllability of medicine release performance. The scaffold is convenient to implant and is invasive-less and low-cost.

The invention relates to antisense oligodeoxynucleotide sequence aiming at a drug resistant gene mecA of a methicillin resistant staphylococcus aureus (MRSA), preparation for medicines containing the antisense oligodeoxynucleotide sequence, and application of the antisense oligodeoxynucleotide sequence. The antisense oligodeoxynucleotide sequence is characterized in that the antisense oligodeoxynucleotide sequence can be combined with different regions of the drug resistant gene mecA of the MRSA, and block the expression of the drug resistant gene mecA; the base sequence of the antisense oligodeoxynucleotide is PS-ODNs01-20; and the antisense oligodeoxynucleotide can be combined with a specific site of a target gene, so as to inhibit the expression of the drug resistant gene, restore the sensitivity of MRSA to beta-lactam antibiotics, and effectively resist the drug resistance of MRSA.

The invention discloses an antisense deoxyribozyme-DNAzyme23. The antisense deoxyribozyme disclosed by the invention adopts an effector molecule RNAIII in the staphylococcus aureus agr quorum-sensing system as a target spot, does not affect the growth state of the bacterium, can effectively block an agr signaling pathway, can significantly weaken the bacterial virulence and particularly can significantly reduce the pathogenicity of methicillin-resistant staphylococcus aureus. The antisense deoxyribozyme has the advantages of high specificity, low toxicity, safety and difficulty in inducing the increase of bacterial drug resistance and the like.

New 1,3-dipenyl pyrazole derived azomethines and N-aryl amines have been synthesized. These anti-MRSA agents combat MRSA and other infections. These azomethine and N-arylamine derivatives of benzoic acid provide combat MRSA and other infections.

The invention discloses an ursolic acid derivative, a preparation method thereof, and an application thereof in the preparation of a drug for treating methicillin-resistant Staphylococcus aureus (MRSA) infection. The preparation method comprises the following steps: oxidizing ursolic acid by a Sarrett reagent to obtain a 3-hydroxy oxidation product of ursolic acid, and carrying out reductive amination on the 3-hydroxy oxidation product of ursolic acid by isopropyl titanate and sodium triacetoxyborohydride in order to prepare the ursolic acid derivative. Anti-MRSA activity test proves that theMIC of the obtained ursolic acid derivative on MRSA test strains is 16-32 [mu]g / mL, the anti-MRSA activity of the ursolic acid derivative is 4-8 times higher than that of the ursolic acid, and the derivative can form a salt together with equimolar hydrochloric acid in order to significantly improve the water solubility. The ursolic acid derivative has a significant anti-MRSA activity and a good development prospect, and can be used to prepare the drug for treating the MRSA infection.

The invention discloses application of water extract, ethanol extract, ethanol aqueous solution extract of Nauclea officinalis and corresponding petroleum ether abstract, ethyl acetate abstract, n-butanol abstract and water abstract of Nauclea officinalis to preparation of medicaments for resisting methicillin-resistant Staphylococcus aureus (MRSA). At the same time, the invention discloses a preparation method of the above extracts or abstracts. The experimental results show that water extract, ethanol extract, ethanol aqueous solution extract of Nauclea officinalis and corresponding ethyl acetate abstract, n-butyl alcohol abstract and water abstract have strong effect in resisting MRSA, and an ethyl acetate extraction position of 70% ethanol extract of Nauclea officinalis has the highest activity.

An anti-methicillin-resistant Staphylococcus aureus agent (anti-MRSA agent) and an anti-vancomycin-resistant Enterococcus agent (anti-VRE agent) contain as an active ingredient an Oobagi extract extracted from Oobagi with an extraction solvent including at least an organic solvent. Alternatively, the anti-MRSA agent and the anti-VRE agent contain as an active ingredient at least one selected from nymphaeol-A, nymphaeol-B, and nymphaeol-C.

The invention relates to a novel multifunctional nano drug delivery system of MRSA (Methicillin-Resistant Staphylococcus Aureus) equisetin and a derivative thereof as well as a preparation and application of the nano drug delivery system in skin soft-tissue infection MRSA, with the combination of nano techniques and electrostatic spinning techniques, nano electrostatic spinning yarns which are applied to skin soft-tissue infection and have the advantages of being large in specific surface area, high in porosity, good in air and moisture permeability and the like are prepared from the nano drugdelivery system, and a novel clinical treatment scheme is provided for skin soft-tissue infection MRSA. By adopting the nano drug delivery system, not only are problems of drug delivery systems for treating skin soft-tissue infection MRSA of MRSA equisetin and the derivative thereof solved, but also the bioavailability of medicines is improved, dual slow release is achieved, and the nano drug delivery system can be applied to treatment on skin soft-tissue infection.

The invention relates to an iridoid compound with the general formula I-III and application of the in-vivo metabolite of the iridoid compound in preparing a drug-resistance bacterium infection resisting drug. It is found through in-vivo and in-vitro MRBS resisting experiments that the iridoid compound and the metabolite of the iridoid compound have remarkable drug-resistance bacterium resisting activity and can be used for being developed into the drug-resistance bacterium resisting drug.

The invention relates to antisense oligodeoxynucleotide sequence aiming at a drug resistant gene mecA of a methicillin resistant staphylococcus aureus (MRSA), preparation for medicines containing the antisense oligodeoxynucleotide sequence, and application of the antisense oligodeoxynucleotide sequence. The antisense oligodeoxynucleotide sequence is characterized in that the antisense oligodeoxynucleotide sequence can be combined with different regions of the drug resistant gene mecA of the MRSA, and block the expression of the drug resistant gene mecA; the base sequence of the antisense oligodeoxynucleotide is PS-ODNs01-20; and the antisense oligodeoxynucleotide can be combined with a specific site of a target gene, so as to inhibit the expression of the drug resistant gene, restore the sensitivity of MRSA to beta-lactam antibiotics, and effectively resist the drug resistance of MRSA.

The invention relates to a preparation method and application of a methicillin-resistant Staphylococcus aureus (MRSA) vaccine recombinant protein I12C. The fusion protein is composed of two active segments of MRSA iron ion surface determination protein IsdB and an active segment of ClfA antigen molecule, and the segments are used by connecting peptides. The fusion protein has the advantages of high purity, high expression quantity, high efficiency and high safety, and is convenient for separation and purification. The preparation method is simple and easy to amplify, and has favorable repetitiveness. After using the aluminum adjuvant, the fusion protein can be used for preparing an anti-MRSA subunit vaccine and preparing a detection kit for MRSA. The animal experiment proves that the fusion protein can effectively stimulate the mechanisms to generate high humoral immune response and favorable immunoprotection function of resisting MRSA infection.

Mouse monoclonal antibodies specifically recognizing the Penicillin Binding Protein 2a (PBP2a) derived from a strain of Methicillin-Resistant Staphylococcus aureus (MRSA) were produced and characterized. The immunogen used to generate an immune response in a mouse was a PBP2a recombinant protein derived from a strain of Methicillin-Resistant Staphylococcus aureus (MRSA). The data showed that both monoclonal antibodies of the disclosure were able to distinguish MRSA from MSSA bacteria. The monoclonal antibodies have distinct recognition patterns for the regions of the PBP2a protein sequence. Epitope mapping has localized regions of the PBP2a protein specifically recognized by one or both of the monoclonal antibodies. The monoclonal antibodies of the present disclosure having the ability to distinguish between MRSA and MSSA strains can be useful as the basis for a diagnostic assay useful in the clinical setting for determining whether and which antibiotics to administer to a patient.

The invention provides a photoresponsive release of NO anti-MRSA biofilm gold nanocage material and its preparation method and application, and relates to the field of biomedical engineering materials. The preparation method provided by the present invention utilizes the sulfhydryl groups on TCF to form gold-sulfur bonds with gold nanocage AuNC to realize the effective loading of NO donor TCF on gold nanocages, and the prepared AuNC@TCF will release slowly at physiological temperature NO, thereby promoting MRSA from the state of biofilm to the state of free bacteria. AuNC@TCF can be irradiated with near-infrared light to heat up rapidly, which can accelerate the release of NO from TCF, and further synergize with NO and photothermal therapy for antibacterial. The AuNC@TCF provided by the invention has obvious antibacterial and biofilm dissipating effects, and can be used as an antibacterial drug, wound healing promotion or anti-inflammatory drug, and shows an important application prospect in anti-biofilm.

Disclosed are an anti-methicillin-resistant Staphylococcus aureus agent (an anti-MRSA agent) and an anti-vancomycin-resistant Enterococcus agent (an anti-VRE agent), each of which comprises, as an active ingredient, an Macaranga tanarius extract that is extracted from a plant Macaranga tanarius with an extraction solvent comprising at least an organic solvent. Alternatively, each of the anti-MRSA agent and the anti-VRE agent may comprise at least one member selected from nymphaeol-A, nymphaeol-B and nymphaeol-C as an active ingredient.

The invention discloses a fructus schisandrae quality detecting method based on a spectrum-effect relationship. The fructus schisandrae quality detecting method comprises the following steps that firstly, a UPLC-MS fingerprint spectrum of anti-MRSA in-vitro bacteriostatic active components of a to-be-detected fructus schisandrae test sample is established, a characteristic peak is screened, then the screened characteristic peak area is substituted into a spectrum-effect mathematical model for calculation, and the quality of the fructus schisandrae test sample is judged according to the resultobtained by calculation. According to the fructus schisandrae quality detecting method, the quality of a fructus schisandrae product is judged in the mode of combination of the fingerprint spectrum and the mathematical model, disturbance of third party factors can be avoided, complex pharmacology experiments are avoided, individual deviation of animals is avoided, and the antibacterial effect of the anti-MRSA active site of the fructus schisandrae can be basically determined quickly and clearly.

Methods of use of an anti-methicillin-resistant Staphylococcus aureus agent (anti-MRSA agent) and an anti-vancomycin-resistant Enterococcus agent (anti-VRE agent) contain as an active ingredient a Macaranga tanarius extract extracted from Macaranga tanarius with an extraction solvent including at least an organic solvent are disclosed. The anti-MRSA agent and the anti-VRE agent contain as an active ingredient at least one selected from nymphaeol-A, nymphaeol-B, and nymphaeol-C.